

Supplementary Table 1:

Reference	Serum type	Dosage	Measured on day	Assay	Variants tested	Data derived from:	Figure Lab Number
1	Convalescent	n/a	> 1 month post recovery (severe and non-severe)	Live virus end point microneutralisation assay, ID50	Ancestral (WA1) Alpha/B.1.1.7 Beta/B.1.351	Fig 3b and Fig 4b, raw data kindly provided	Laboratory 1
	mRNA-1273	100 µg	15 days post second dose				
	BNT162b2	ns	> 7 days post second dose				
2	Convalescent	n/a	> 1 month post recovery (severe and non-severe)	Live virus end point microneutralisation assay, ID50	Ancestral (WA1) Gamma/P.1	Fig S1C and D, raw data kindly provided	Laboratory 1
	mRNA-1273	100 µg	15 days post second dose				
	BNT162b2		>7 days post second dose				
3	Convalescent	n/a	4-9 weeks post infection	Live virus focus reduction neutralisation test, FRNT50	Ancestral (Victoria) Beta/B.1.351	Fig 2c/Table S1a	Laboratory 2
	BNT162b2	30 µg	7-17 days post second dose			Fig 3c/Table S2	
	CHAdOx1/AZD1222	Standard or half dose	14 or 28 days post second dose			Fig 3d/Table S2	
4	Convalescent	n/a	4-9 weeks post infection	Live virus focus reduction neutralisation test, IC50	Ancestral (Victoria) Gamma/P.1	Table S4A	Laboratory 2
	BNT162b2	30 µg	4-17 days post second dose			Table S5	
	CHAdOx1/AZD1222	Standard or half dose	14 or 28 days post second dose				
5	Convalescent	n/a	4-9 weeks post infection	Live virus focus reduction neutralisation test FRNT50	Ancestral (Victoria) Alpha/B.1.1.7	Fig5a, raw data kindly provided	Laboratory 2
	BNT162b2	30 µg	7-17 days post second dose			Fig5b, raw data kindly provided	
	CHAdOx1/AZD1222	Standard dose (5×10^{10}) or half dose	14 or 28 days post second dose			Fig5c, raw data kindly provided	
6	Convalescent	n/a	4-9 weeks post infection	Live virus focus reduction neutralisation test, FRNT50	Delta/B.1.617.2	Table S4	Laboratory 2
	BNT162b2	30 µg	7-17 days post second dose				
	CHAdOx1/AZD1222	Standard or half dose	14 or 28 days post second dose				
7	Convalescent	n/a	168-197 days post symptom onset. Mild/moderate, severe and critical disease	Live virus, GFP-split reporter system, IC50	D614G (hCoV-19/France/GE1973/2020) Alpha/B.1.1.7 Beta/B.1.351	Fig 2b, raw data kindly provided	Laboratory 3
8	Convalescent	n/a	6 months post symptom onset	Live virus, GFP-split reporter system, IC50	D614G (hCoV-19/France/GE1973/2020) Alpha/B.1.1.7 Beta/B.1.351 Delta/B.1.617.2	Fig 4a, raw data kindly supplied	Laboratory 3
	BNT162b2	ns	Ave 36 days (32-46)				
9	Convalescent	n/a	~ 1 month post mild infection	Live virus focus reduction	Ancestral WA1 with D614G (recombinant) Alpha/B.1.1.7- isolate	Fig 2a,e, raw data kindly provided	Laboratory 4

	BNT162b2	ns	7 days post second dose	neutralisation test, EC50	Beta/B.1.351 spike (recombinant)	Fig 4a,d, raw data kindly provided	
10	Convalescent	n/a	10-102 days post infection	Live virus Plaque reduction neutralisation test PRNT50	Ancestral Gamma/P.1	Supplementary table 4	Laboratory 5
11	Convalescent	n/a	6-43 days post symptom onset/first PCR test positive	Live virus focus reduction neutralisation test, IC50	Ancestral (hCoV- 19/England/02/2020) Alpha/B.1.1.7 Beta/B.1.351	2b, raw data kindly provided	Laboratory 6
12	BBV152	ns	ns	Live virus Plaque reduction neutralisation test PRNT50	Ancestral Alpha/B.1.1.7	Fig 1b	Laboratory 7
13	Convalescent	n/a	1 to 8 weeks after resolution of infection or 2 to 10 weeks after the most recent positive SARS- CoV-2 test.	Lentivirus based pseudovirus assay, ID50	Ancestral with D614G Alpha/B.1.1.7	Fig 2a/Table S1	Laboratory 8
	mRNA-1273	100 µg	28 days post second dose				
	NVX-CoV2373	5 µg protein + Matrix M	14 days post second dose				
14	Convalescent	n/a	1 to 8 weeks after resolution of infection or 2 to 10 weeks after the most recent positive SARS- CoV-2 test.	Lentivirus based pseudovirus assay, ID50	Ancestral with D614G Beta/B.1.351	Fig 1a/Table S2	Laboratory 8
	mRNA-1273	100 µg	28 days post second dose				
	NVX-CoV2373	5 µg protein + Matrix M	14 days post second dose				
15	Convalescent	n/a	2-85 days post + PCR test	Live virus focus reduction neutralisation test, ID50	B.1.126 ('WT') Beta/B.1.351	Fig 4a	Laboratory 9
	BNT162b2	ns	7-16 days post second dose				
16	Convalescent	n/a	31-91 days post symptom onset	Live virus focus reduction neutralisation test, FRNT50	Ancestral (WA1) Kappa/B.1.617.1	Fig 1a/Supplementary table 2	Laboratory 10
	BNT162b2	ns	7-27 days post second dose			Fig 1c/ Supplementary table 3	
	mRNA-1273	ns	35-51 days post second dose			Fig 1b/ Supplementary table 4	
17	BNT162b2	ns	Median: 28 days post second dose	Live virus focus reduction neutralisation test, IC50	Ancestral (hCoV19/England/02/2020) D614G Alpha/B.1.1.7 Beta/B.1.351 Delta/B.1.617.2	https://github.com/davidlb/Cric_k-UCLH-Legacy-VOCs-2021-05	Laboratory 11

ns. Not specified

Supplementary Table 2:

Study	Vaccine	Trial Started (Day)	Variants compared			Measure of effectiveness	Efficacy against severe disease			Trial design	Data derived from
			Alpha/B.1.1.7	Beta/B.1.351	Delta/B.1.617.2		Alpha/B.1.1.7	Beta/B.1.351	Delta/B.1.617.2		
18	BNT162b2	14 days post 2 nd dose	89.5%*	75%#	N/A	Any documented infection	100% (95% CI: 81.7-100)	100% (95% CI: 73.7-100)	N/A	Test negative case control	Table 1
19	BNT162b2	14 days post 2 nd dose	93.4%		87.9%	Symptomatic disease	ND			Test negative case control	Table 2
	ChAdOx1 nCoV-19	14 days post 2 nd dose	66.1%		59.8%	Symptomatic disease	ND				
20	ChAdOx1 nCoV-19	14 days post 2 nd dose		10.4%		Symptomatic disease	Not able to report.			Randomized controlled trial	Table 2
21	NVX-CoV2373	7 days post 2 nd dose		51%^		Symptomatic disease	Not able to report			Randomized controlled trial	In text
22	NVX-CoV2373	7 days post 2 nd dose	86.3%			PCR confirmed symptomatic COVID, mild, moderate or severe	Not specifically reported (only 5 cases of severe disease, all in placebo group)			Randomized controlled trial	Fig 4
23	Ad26.COV2.S	28 days post dose		64%		Moderate/ severe disease		81.7%		Randomized controlled trial	Table 3
24	BNT162b2	14 days post 2 nd dose	92%*		79% ^δ	PCR confirmed infection	Not reported			Test negative case control	Text
	ChAdOx1 nCoV-19	14 days post 2 nd dose	73%*		60% ^δ						

*S-gene “target failure” PCR used as indicator of B.1.1.7, # Assumed to be B.1.351 if not B.1.117, δ S-gene positive PCR assumed to be B.1.617.2

^ HIV-negative population

Supplementary Table 3:

Source of uncertainty		Parameter in model	Estimated value	Standard error in value	Reference
Model parameters (\log_{10} of the 50% protective neutralisation titre and natural log of the logistic slope parameter)	Symptomatic	n_{50}, k_{log}	1.13, -0.697	Covariance matrix from fit	25
	Severe	n_{50}, k_{log}	1.12, -1.509	Covariance matrix from fit	25
Standard deviation of neutralisation titres for each vaccine		σ_{all}	0.46	0.022	25
Mean (\log_{10}) neutralisation level of a vaccine against ancestral virus		μ_s	Table S4 of reference (Ref)	Max. value across studies, 0.20	25
Fold-change (\log_{10}) in neutralisation titre against each variant		$\log_{10} \bar{F}^v$	Fig. S3	0.015-0.029	Current study

Table S3: Sources of uncertainty in model predictions of vaccine efficacy against variants. In this table we use k_{log} to denote $\log_e(k)$.

Supplementary Table 4:

Reference	Vaccine	Reference Group	Boosted Group (days post-infection)	Measured on day post-dose	Assay	Fold change (Boosted/Reference) for ancestral virus	Neutralisation titre (fold convalescent) in reference group (Phase I/II trials) ²⁵	Predicted mean neutralisation level after boosting (fold convalescent)	Date derived from	Data on Variants
26	BNT162b2	Naïve, 2 doses	Convalescent, 1 dose (mean:111)	10	Live virus Microneutralisation test, 50% endpoint titre	4.8	2.4	11.4	G/MT titres in text	
27	BNT162b2	Naïve, 2 doses	Convalescent, 2 doses (median: 53)	>14	Live virus, Focus reduction neutralisation test (FRNT50)	3.4	2.4	8.0	Extracted from Figure 2	Alpha, Beta, Gamma
28	BNT162b2 or mRNA-1273	Naïve, 2 doses	Convalescent, 2 doses (median: 247)	19/13 (reference/convalescent)	Pseudovirus neutralisation	5	3.1*	15.7	Mean value given in text	Beta
29	BNT162b2 or mRNA-1273	Naïve, 2 doses	Convalescent, 2 doses (65-275)	7	Pseudovirus neutralisation	9.2	3.1*	28.7	Raw data in supplement appendix	Beta
30	BNT162b2 or mRNA-1273	Naïve, 2 doses	Convalescent, 2 doses	28	Live virus, Plaque reduction neutralisation assay (PRNT50)	2	3.1*	6.1	Raw data kindly supplied	Alpha, Beta, Gamma, Delta, Epsilon, Eta, Iota, Kappa
31 and 32	mRNA-1273 (50 µg)	Naïve, 2 doses	mRNA-1273 boosted (177-226 post second dose)	7/15 (reference/boost)	Pseudovirus neutralisation	2.5	4.1	10.1	Figure 3 (31) and Figure 1 (32)	Beta, Gamma
33	CoronaVac	Naïve, 2 doses	CoronaVac 3 rd dose, (180 post-second dose)	14	Live virus, microneutralisation test	4.9	0.17	0.82	Figure 2	

* Geometric mean of neutralisation levels for BNT162b2 and mRNA-1273 reported in Phase I/II trials as summarised in reference 25

References:

1. Wang, P. et al., Antibody Resistance of Sars-Cov-2 Variants B.1.351 and B.1.1.7. *Nature* **593**, 130-135 (2021).
2. Wang, P. et al., Increased Resistance of Sars-Cov-2 Variant P.1 to Antibody Neutralization. *Cell Host & Microbe* **29**, 747-751.e744 (2021).
3. Zhou, D. et al., Evidence of Escape of Sars-Cov-2 Variant B.1.351 from Natural and Vaccine-Induced Seras. *Cell* **184**, 2348-2361.e2346 (2021).
4. Dejnirattisai, W. et al., Antibody Evasion by the P.1 Strain of Sars-Cov-2. *Cell* **184**, 2939-2954.e2939 (2021).
5. Supasa, P. et al., Reduced Neutralization of Sars-Cov-2 B.1.1.7 Variant by Convalescent and Vaccine Seras. *Cell* **184**, 2201-2211.e2207 (2021).
6. Liu, C. et al., Reduced Neutralization of Sars-Cov-2 B.1.617 by Vaccine and Convalescent Serum. *Cell* (2021).
7. Planas, D. et al., Sensitivity of Infectious Sars-Cov-2 B.1.1.7 and B.1.351 Variants to Neutralizing Antibodies. *Nature Medicine* **27**, 917-924 (2021).
8. Planas, D. et al., Reduced Sensitivity of Sars-Cov-2 Variant Delta to Antibody Neutralization. *Nature* (2021).
9. Chen, R. E. et al., Resistance of Sars-Cov-2 Variants to Neutralization by Monoclonal and Serum-Derived Polyclonal Antibodies. *Nature Medicine* **27**, 717-726 (2021).
10. Souza, W. M. et al., Neutralisation of Sars-Cov-2 Lineage P.1 by Antibodies Elicited through Natural Sars-Cov-2 Infection or Vaccination with an Inactivated Sars-Cov-2 Vaccine: An Immunological Study. *The Lancet Microbe*.
11. Faulkner, N. et al., Reduced Antibody Cross-Reactivity Following Infection with B.1.1.7 Than with Parental Sars-Cov-2 Strains. *eLife* **10**, e69317 (2021).
12. Sapkal, G. N. et al., Neutralization of Uk-Variant Vui-202012/01 with Covaxin Vaccinated Human Serum. *bioRxiv*, 2021.2001.2026.426986 (2021).
13. Shen, X. et al., Sars-Cov-2 Variant B.1.1.7 Is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines. *Cell Host & Microbe* **29**, 529-539.e523 (2021).
14. Shen, X. et al., Neutralization of Sars-Cov-2 Variants B.1.429 and B.1.351. *New England Journal of Medicine* **384**, 2352-2354 (2021).
15. Becker, M. et al., Immune Response to Sars-Cov-2 Variants of Concern in Vaccinated Individuals. *Nature Communications* **12**, 3109 (2021).
16. Edara, V.-V. et al., Infection and Vaccine-Induced Neutralizing-Antibody Responses to the Sars-Cov-2 B.1.617 Variants. *New England Journal of Medicine* (2021).
17. Wall, E. C. et al., Neutralising Antibody Activity against Sars-Cov-2 Vocis B.1.617.2 and B.1.351 by Bnt162b2 Vaccination. *The Lancet* **397**, 2331-2333 (2021).
18. Abu-Raddad, L. J. et al., Effectiveness of the Bnt162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *New England Journal of Medicine* (2021).
19. Lopez Bernal, J. et al., Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New England Journal of Medicine* (2021).
20. Madhi, S. A. et al., Efficacy of the ChAdOx1 Ncov-19 Covid-19 Vaccine against the B.1.351 Variant. *New England Journal of Medicine* **384**, 1885-1898 (2021).
21. Shinde, V. et al., Efficacy of Nvx-Cov2373 Covid-19 Vaccine against the B.1.351 Variant. *New England Journal of Medicine* **384**, 1899-1909 (2021).
22. Heath, P. T. et al., Safety and Efficacy of Nvx-Cov2373 Covid-19 Vaccine. *New England Journal of Medicine* (2021).
23. Sadoff, J. et al., Safety and Efficacy of Single-Dose Ad26.Cov2.S Vaccine against Covid-19. *N Engl J Med* **384**, 2187-2201 (2021).
24. Sheikh, A. et al., Sars-Cov-2 Delta Vac in Scotland: Demographics, Risk of Hospital Admission, and Vaccine Effectiveness. *The Lancet* **397**, 2461-2462 (2021).
25. Khoury, D. S. et al., Neutralizing Antibody Levels Are Highly Predictive of Immune Protection from Symptomatic Sars-Cov-2 Infection. *Nature Medicine* **27**, 1205-1211 (2021).
26. Anichini, G. et al., Sars-Cov-2 Antibody Response in Persons with Past Natural Infection. *New England Journal of Medicine* **385**, 90-92 (2021).
27. Leier, H. C. et al., Previously Infected Vaccinees Broadly Neutralize Sars-Cov-2 Variants. *medRxiv*, 2021.2004.2025.21256049 (2021).
28. Stamatatos, L. et al., Mrna Vaccination Boosts Cross-Variant Neutralizing Antibodies Elicited by Sars-Cov-2 Infection. *Science* **372**, 1413 (2021).
29. Goel, R. R. et al., Distinct Antibody and Memory B Cell Responses in Sars-Cov-2 Naïve and Recovered Individuals after Mrna Vaccination. *Science Immunology* **6**, eabi6950 (2021).
30. Lucas, C. et al., Impact of Circulating Sars-Cov-2 Variants on Mrna Vaccine-Induced Immunity in Uninfected and Previously Infected Individuals. *medRxiv*, 2021.2007.2014.21260307 (2021).
31. Wu, K. et al., Preliminary Analysis of Safety and Immunogenicity of a Sars-Cov-2 Variant Vaccine Booster. *medRxiv*, 2021.2005.2005.21256716 (2021).
32. Choi, A. et al., Serum Neutralizing Activity of Mrna-1273 against Sars-Cov-2 Variants. *bioRxiv*, 2021.2006.2028.449914 (2021).
33. Pan, H. et al., Immunogenicity and Safety of a Third Dose, and Immune Persistence of Coronavac Vaccine in Healthy Adults Aged 18-59 Years: Interim Results from a Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial. *medRxiv*, 2021.2007.2023.21261026 (2021).